Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 176

1.

Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.

Xie W, Yang M, Chan J, Sun T, Mucci LA, Penney KL, Lee GM, Kantoff PW.

Prostate. 2016 Feb 5. doi: 10.1002/pros.23160. [Epub ahead of print]

PMID:
26847995
2.

Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA.

Am J Clin Nutr. 2016 Jan 27. pii: ajcn118703. [Epub ahead of print]

PMID:
26817504
3.

Risk of prostate cancer specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.

Rudman SM, Gray KP, Batista JL, Pitt MJ, Giovannucci EL, Harper PG, Loda M, Mucci LA, Sweeney CJ.

BJU Int. 2016 Jan 25. doi: 10.1111/bju.13428. [Epub ahead of print]

PMID:
26805930
4.

Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort.

Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2016 Jan 16. pii: bgw001. [Epub ahead of print]

PMID:
26775038
5.

Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.

Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K, Koskenvuo M, Holm NV, Heikkilä K, Pukkala E, Skytthe A, Adami HO, Kaprio J; Nordic Twin Study of Cancer (NorTwinCan) Collaboration.

JAMA. 2016 Jan 5;315(1):68-76. doi: 10.1001/jama.2015.17703.

PMID:
26746459
6.

Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.

Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM.

Eur Urol. 2015 Dec 23. pii: S0302-2838(15)01211-7. doi: 10.1016/j.eururo.2015.12.003. [Epub ahead of print]

PMID:
26724257
7.

Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study.

Markt SC, Flynn-Evans EE, Valdimarsdottir UA, Sigurdardottir LG, Tamimi RM, Batista JL, Haneuse S, Lockley SW, Stampfer M, Wilson KM, Czeisler CA, Rider JR, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2015 Dec 16. [Epub ahead of print]

PMID:
26677208
8.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

PMID:
26615022
9.

The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.

Möller S, Mucci LA, Harris JR, Scheike T, Holst K, Halekoh U, Adami HO, Czene K, Christensen K, Holm NV, Pukkala E, Skytthe A, Kaprio J, Hjelmborg JB.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-50. doi: 10.1158/1055-9965.EPI-15-0913. Epub 2015 Nov 10.

PMID:
26554920
10.

Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.

Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K.

Clin Cancer Res. 2016 Feb 1;22(3):765-72. doi: 10.1158/1078-0432.CCR-15-0101. Epub 2015 Oct 21.

PMID:
26490316
11.

Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.

Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA.

Prostate. 2015 Dec;75(16):1926-33. doi: 10.1002/pros.23090. Epub 2015 Sep 7.

PMID:
26469352
12.

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.

Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM.

Clin Cancer Res. 2016 Jan 15;22(2):448-58. doi: 10.1158/1078-0432.CCR-15-0256. Epub 2015 Oct 7.

PMID:
26446945
13.

Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.

Binder M, Shui IM, Wilson KM, Penney KL; PRACTICAL/ELLIPSE Consortium, Mucci LA, Kibel AS.

Cancer Causes Control. 2015 Dec;26(12):1751-9. doi: 10.1007/s10552-015-0668-3. Epub 2015 Sep 25.

PMID:
26407952
14.

Body size across the life course and prostate cancer in the Health Professionals Follow-up Study.

Möller E, Wilson KM, Batista JL, Mucci LA, Bälter K, Giovannucci E.

Int J Cancer. 2016 Feb 15;138(4):853-65. doi: 10.1002/ijc.29842. Epub 2015 Sep 23.

PMID:
26355806
15.

Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden.

Ahrenfeldt LJ, Skytthe A, Möller S, Czene K, Adami HO, Mucci LA, Kaprio J, Petersen I, Christensen K, Lindahl-Jacobsen R.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1622-8. doi: 10.1158/1055-9965.EPI-15-0317. Epub 2015 Aug 17.

PMID:
26282631
16.

Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study.

Van Blarigan EL, Gerstenberger JP, Kenfield SA, Giovannucci EL, Stampfer MJ, Jones LW, Clinton SK, Chan JM, Mucci LA.

Cancer Prev Res (Phila). 2015 Oct;8(10):962-7. doi: 10.1158/1940-6207.CAPR-15-0132. Epub 2015 Aug 14.

PMID:
26276753
17.

ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).

Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, Brennan P, Bueno-de-Mesquita HB, Gapstur SM, Giovannucci E, Haiman C, Henderson B, Hoover RN, Hunter DJ, Key TJ, Khaw KT, Canzian F, Larranga N, Le Marchand L, Ma J, Naccarati A, Siddiq A, Stampfer MJ, Stattin P, Stevens VL, Stram DO, Tjønneland A, Travis RC, Trichopoulos D, Ziegler RG, Lindstrom S, Kraft P, Mucci LA, Choueiri TK, Wilson KM.

Prostate. 2015 Nov;75(15):1677-81. doi: 10.1002/pros.23035. Epub 2015 Aug 13.

PMID:
26268879
18.

Persistence of Trichomonas vaginalis serostatus in men over time.

Sutcliffe S, Alderete JF, Neace C, Joyce PA, Gaydos CA, Huth JI, Mucci LA, Signorello LB.

Cancer Causes Control. 2015 Oct;26(10):1461-6. doi: 10.1007/s10552-015-0642-0. Epub 2015 Jul 30.

PMID:
26223890
19.

No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Case-Control Study.

Liu H, Shui IM, Platz EA, Mucci LA, Giovannucci EL.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1632-4. doi: 10.1158/1055-9965.EPI-15-0367. Epub 2015 Jul 19.

PMID:
26189769
20.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW.

JAMA Oncol. 2015 Jul;1(4):495-504. doi: 10.1001/jamaoncol.2015.0829. Erratum in: JAMA Oncol. 2015 Jul;1(4):544.

PMID:
26181260
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk